J Korean Acad Nurs.  2015 Dec;45(6):783-801. 10.4040/jkan.2015.45.6.783.

Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review

• Chu SH
• Lee YJ
• Lee YJ
• Cleeland C

• KMID: 2363103
• DOI: http://doi.org/10.4040/jkan.2015.45.6.783

Abstract

PURPOSE
The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool.
METHODS
A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability.
RESULTS
Ten (41.7%) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3%) and only 29.2% of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute-Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI.
CONCLUSION
To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.

Keyword

Oxaliplatin; Peripheral nervous system diseases; Symptom assessment; Psychometrics

MeSH Terms

Activities of Daily Living
Antineoplastic Agents/*adverse effects/therapeutic use
Databases, Factual
Humans
Neoplasms/drug therapy
Organoplatinum Compounds/*adverse effects/therapeutic use
Peripheral Nervous System Diseases/*etiology
Psychometrics
Antineoplastic Agents
Organoplatinum Compounds

Figure

• 

  Figure 1 Flow of review process.

Reference

1. Bécouarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: Available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol. 2001; 40(3):265–272. DOI: 10.1016/S1040-8428(01)00169-X.

2. Otsu S, Hirashima Y, Nishikawa K, Sakashita H, Morinaga R, Watanabe K, et al. Neurological toxicity in metastatic colorectal cancer patients treated with modified FOLFOX6 plus bevacizumab. Jpn Clin Med. 2014; 5:19–23. DOI: 10.4137/jcm.s15553.

3. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol. 2007; 3(2):281–294. DOI: 10.1517/17425255.3.2.281.

4. Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: Many questions with few answers. Clin Colorectal Cancer. 2014; 13(2):73–80. DOI: 10.1016/j.clcc.2013.11.004.

5. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005; 5:116. DOI: 10.1186/1471-2407-5-116.

6. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol. 2004; 22(23):4753–4761. DOI: 10.1200/jco.2004.03.119.

7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938–2947.

8. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, et al. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer. 2012; 11(2):93–100. DOI: 10.1016/j.clcc.2011.10.004.

9. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014; 32(10):997–1005. DOI: 10.1200/jco.2013.52.0536.

10. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003; 61(9):1297–1300. DOI: 10.1212/01.WNL.0000092015.03923.19.

11. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998; 9(7):739–744.

12. Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011; 34(4):E10–E20. DOI: 10.1097/NCC.0b013e31820251de.

13. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: A patient perspective. Support Care Cancer. 2012; 20(11):2959–2967. DOI: 10.1007/s00520-012-1428-5.

14. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17(12):1483–1491. DOI: 10.1007/s00520-009-0613-7.

15. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005; 5:Suppl 1. S38–S46. DOI: 10.3816/CCC.2005.s.006.

16. Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the national cancer institutesponsored clinical trials networks. J Clin Oncol. 2007; 25(32):5070–5077. DOI: 10.1200/jco.2007.12.7670.

17. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010; 6(12):657–666. DOI: 10.1038/nrneurol.2010.160.

18. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007; 60(1):34–42. DOI: 10.1016/j.jclinepi.2006.03.012.

19. Windle G, Bennett KM, Noyes J. A methodological review of resilience measurement scales. Health Qual Life Outcomes. 2011; 9:8. DOI: 10.1186/1477-7525-9-8.

20. Larsen CM, Juul-Kristensen B, Lund H, Søgaard K. Measurement properties of existing clinical assessment methods evaluating scapular positioning and function. A systematic review. Physiother Theory Pract. 2014; 30(7):453–482. DOI: 10.3109/09593985.2014.899414.

21. Silva PF, Quintino LF, Franco J, Faria CD. Measurement properties and feasibility of clinical tests to assess sit-to-stand/stand-tosit tasks in subjects with neurological disease: A systematic review. Braz J Phys Ther. 2014; 18(2):99–110. DOI: 10.1590/S1413-35552012005000155.

22. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8(2):147–159.

23. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33(1):15–49. DOI: 10.1053/j.seminoncol.2005.12.010.

24. Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992; 69(4):893–900. DOI: 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X.

25. Kautio AL, Haanpää M, Kautiainen H, Leminen A, Kalso E, Saarto T. Oxaliplatin scale and national cancer institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res. 2011; 31(10):3493–3496.

26. Smith EM, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008; 35(1):96–102. DOI: 10.1188/08.onf.96-102.

27. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer. 2005; 41(8):1135–1139. DOI: 10.1016/j.ejca.2005.02.012.

28. Lee EH, Kim CJ, Kim EJ, Chae HJ, Cho SY. Measurement properties of self-report questionnaires published in Korean nursing journals. J Korean Acad Nurs. 2013; 43(1):50–58. DOI: 10.4040/jkan.2013.43.1.50.

29. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. COSMIN checklist manual [Internet]. Amsterdam, NL: COSMIN Group;2012. cited 2015 January 17. Available from: http://www.cosmin.nl/images/upload/files/COSMIN%20checklist%20manual%20v9.pdf.